Biohaven Pharmaceutical Holding Share Holder Equity 2016-2022 | BHVN

Biohaven Pharmaceutical Holding share holder equity from 2016 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
  • Biohaven Pharmaceutical Holding share holder equity for the quarter ending June 30, 2022 was $-0.806B, a 76.43% increase year-over-year.
  • Biohaven Pharmaceutical Holding share holder equity for 2021 was $-0.743B, a 89.45% increase from 2020.
  • Biohaven Pharmaceutical Holding share holder equity for 2020 was $-0.392B, a 5182.72% increase from 2019.
  • Biohaven Pharmaceutical Holding share holder equity for 2019 was $-0.007B, a 104.92% decline from 2018.
Biohaven Pharmaceutical Holding Annual Share Holder Equity
(Millions of US $)
2021 $-743
2020 $-392
2019 $-7
2018 $151
2017 $132
2016 $-2
2015 $1
Biohaven Pharmaceutical Holding Quarterly Share Holder Equity
(Millions of US $)
2022-06-30 $-806
2022-03-31 $-466
2021-12-31 $-743
2021-09-30 $-591
2021-06-30 $-457
2021-03-31 $-278
2020-12-31 $-392
2020-09-30 $-214
2020-06-30 $-35
2020-03-31 $122
2019-12-31
2019-09-30 $119
2019-06-30 $187
2019-03-31 $97
2018-12-31 $151
2018-09-30 $66
2018-06-30 $119
2018-03-31 $108
2017-12-31 $132
2017-09-30 $156
2017-06-30 $193
2017-03-31 $20
2016-12-31 $-2
2016-09-30 $0
2016-06-30 $0
2016-03-31
2015-12-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.873B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Enzo Biochem (ENZ) United States $0.105B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00